litlas
Log inCreate account

Allan D. Sniderman

Active 1973–2025

121
Papers
19,587
Citations
82
h-index
116
i10-index

Citations

Citations per year for Allan D. Sniderman1955: 1 citations1974: 2 citations1975: 4 citations1976: 4 citations1977: 4 citations1978: 7 citations1979: 8 citations1980: 7 citations1981: 5 citations1982: 16 citations1983: 14 citations1984: 9 citations1985: 29 citations1986: 60 citations1987: 33 citations1988: 48 citations1989: 41 citations1990: 51 citations1991: 51 citations1992: 45 citations1993: 80 citations1994: 45 citations1995: 54 citations1996: 50 citations1997: 58 citations1998: 81 citations1999: 63 citations2000: 76 citations2001: 78 citations2002: 86 citations2003: 100 citations2004: 157 citations2005: 124 citations2006: 106 citations2007: 100 citations2008: 114 citations2009: 126 citations2010: 119 citations2011: 157 citations2012: 125 citations2013: 147 citations2014: 112 citations2015: 138 citations2016: 119 citations2017: 85 citations2018: 88 citations2019: 328 citations2020: 318 citations2021: 328 citations2022: 301 citations2023: 225 citations2024: 437 citations2025: 210 citations2026: 53 citations1956–1973: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,682 citing papers, 27.7% of this breakdownCanada: 489 citing papers, 8.1% of this breakdownUnited Kingdom: 489 citing papers, 8.1% of this breakdownChina: 378 citing papers, 6.2% of this breakdownNetherlands: 236 citing papers, 3.9% of this breakdownItaly: 218 citing papers, 3.6% of this breakdownAustralia: 210 citing papers, 3.5% of this breakdownGermany: 198 citing papers, 3.3% of this breakdownFrance: 187 citing papers, 3.1% of this breakdownSweden: 155 citing papers, 2.5% of this breakdownSpain: 132 citing papers, 2.2% of this breakdownJapan: 108 citing papers, 1.8% of this breakdown
0%27.7%Other 26%

Institutions

Fields

  • Medicine76.3%
  • Biochemistry, Genetics and Molecular Biology12.2%
  • Immunology and Microbiology2.9%
  • Neuroscience1.9%
  • Nursing1.8%
  • Health Professions0.9%
  • Other4%

Topics

  • Lipoproteins and Cardiovascular Health10.5%
  • Diabetes, Cardiovascular Risks, and Lipoproteins10.4%
  • Adipokines, Inflammation, and Metabolic Diseases4.3%
  • Cancer, Lipids, and Metabolism2.9%
  • Adipose Tissue and Metabolism2.6%
  • Lipid metabolism and disorders2.5%
  • Other66.8%

Coauthors

All papers

Open in search
  1. Apolipoprotein B Particles and Cardiovascular Disease

    Authors: Allan D. Sniderman, George Thanassoulis, Tamara Glavinovic, Ann Marie Návar, Michael Pencina, Alberico L. Catapano, Brian A. Ference - JAMA Cardiology 2019 cited by 575

  2. A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk

    Authors: Allan D. Sniderman, Ken Williams, John H. Contois, Howard M. Monroe, Matthew McQueen, Jacqueline de Graaf, Curt D. Furberg - Circulation Cardiovascular Quality and Outcomes 2011 cited by 643

  3. Physiological Bases for the Superiority of Apolipoprotein B Over Low‐Density Lipoprotein Cholesterol and Non–High‐Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk

    Authors: Tamara Glavinovic, George Thanassoulis, Jacqueline de Graaf, Patrick Couture, Robert A. Hegele, Allan D. Sniderman - Journal of the American Heart Association 2022 cited by 152

  4. Quantifying Importance of Major Risk Factors for Coronary Heart Disease

    Authors: Michael Pencina, Ann Marie Návar, Daniel Wojdyla, Robert J. Sanchez, Irfan Khan, Joseph Elassal, Ralph B. D’Agostino, Eric D. Peterson, Allan D. Sniderman - Circulation 2019 cited by 245

  5. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

    Authors: Matthew McQueen, Steven Hawken, Xingyu Wang, Stephanie Ôunpuu, Allan D. Sniderman, Jeffrey L. Probstfield, Krisela Steyn, John E. Sanderson, Mohammad Hasani, Э. Г. Волкова, Khawar Kazmi, Salim Yusuf - The Lancet 2008 cited by 868

  6. Discordance among apoB, non–high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention

    Authors: Allan D. Sniderman, Line Dufresne, Karol M. Pencina, S. Bilgiç, George Thanassoulis, Michael Pencina - European Heart Journal 2024 cited by 92

  7. Cholesteryl Ester Transfer Protein Inhibition Reduces Major Adverse Cardiovascular Events by Lowering Apolipoprotein B Levels

    Authors: Adam J. Nelson, Allan D. Sniderman, Marc Ditmarsch, Mary R. Dicklin, Stephen J. Nicholls, Michael H. Davidson, John J.P. Kastelein - International Journal of Molecular Sciences 2022 cited by 71

  8. Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease

    Authors: Ann Marie Navar‐Boggan, Eric D. Peterson, Ralph B. D’Agostino, Benjamin Neely, Allan D. Sniderman, Michael Pencina - Circulation 2015 cited by 409

  9. Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol

    Authors: John H. Contois, Michel R. Langlois, Christa M. Cobbaert, Allan D. Sniderman - Journal of the American Heart Association 2023 cited by 45

  10. Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification

    Authors: John T. Wilkins, Ron Li, Allan D. Sniderman, Cheeling Chan, Donald M. Lloyd‐Jones - Journal of the American College of Cardiology 2016 cited by 185

  11. Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials

    Authors: George Thanassoulis, Ken Williams, Keying Ye, Robert D. Brook, Patrick Couture, Patrick R. Lawler, Jacqueline de Graaf, Curt D. Furberg, Allan D. Sniderman - Journal of the American Heart Association 2014 cited by 146

  12. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C

    Authors: Michael Pencina, Ralph B. D’Agostino, Tomasz Zdrojewski, Ken Williams, George Thanassoulis, Curt D. Furberg, Eric D. Peterson, Ramachandran S. Vasan, Allan D. Sniderman - European Journal of Preventive Cardiology 2015 cited by 161

  13. Trajectories of Non–HDL Cholesterol Across Midlife

    Authors: Karol M. Pencina, George Thanassoulis, John T. Wilkins, Ramachandran S. Vasan, Ann Marie Návar, Eric D. Peterson, Michael Pencina, Allan D. Sniderman - Journal of the American College of Cardiology 2019 cited by 103

  14. Ethnic Variation in Fat and Lean Body Mass and the Association with Insulin Resistance

    Authors: Scott A. Lear, Simi Kohli, Gregory P. Bondy, André Tchernof, Allan D. Sniderman - The Journal of Clinical Endocrinology & Metabolism 2009 cited by 172

  15. The clinical utility of apoB versus LDL-C/non-HDL-C

    Authors: Ciaran Kohli‐Lynch, George Thanassoulis, Andrew E. Moran, Allan D. Sniderman - Clinica Chimica Acta 2020 cited by 47

  16. Hypertrophy and hyperplasia of abdominal adipose tissues in women

    Authors: Renée Drolet, Caroline Richard, Allan D. Sniderman, Jacques Mailloux, Michel Fortier, Céline Huot, Caroline Rhéaume, André Tchernof - International Journal of Obesity 2007 cited by 237

  17. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk

    Authors: Allan D. Sniderman, Annie St‐Pierre, Bernard Cantin, Gilles R. Dagenais, Jean‐Pierre Després, Benoı̂t Lamarche - The American Journal of Cardiology 2003 cited by 224

  18. Age as a modifiable risk factor for cardiovascular disease

    Authors: Allan D. Sniderman, Curt D. Furberg - The Lancet 2008 cited by 186

  19. The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering

    Authors: Michael Pencina, Karol M. Pencina, Donald M. Lloyd‐Jones, Alberico L. Catapano, George Thanassoulis, Allan D. Sniderman - Circulation 2020 cited by 80

  20. Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study

    Authors: Allan D. Sniderman, Shofique Islam, Salim Yusuf, Matthew McQueen - Atherosclerosis 2012 cited by 137

  21. Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women

    Authors: Patrick R. Lawler, Akintunde O. Akinkuolie, Paul M. Ridker, Allan D. Sniderman, Julie E. Buring, Robert J. Glynn, Daniel I. Chasman, Samia Mora - Clinical Chemistry 2017 cited by 109

  22. Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk

    Authors: Allan D. Sniderman, Ann Marie Návar, George Thanassoulis - JAMA Cardiology 2021 cited by 75

  23. Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood

    Authors: John Wilkins, Hongyan Ning, Norrina B. Allen, Alexander R. Zheutlin, Nilay S. Shah, Matthew J. Feinstein, Amanda M. Perak, Sadiya S. Khan, Ankeet S. Bhatt, Ravi V. Shah, Venkatesh L. Murthy, Allan D. Sniderman, Donald M. Lloyd‐Jones - Journal of the American College of Cardiology 2024 cited by 25

  24. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis

    Authors: Allan D. Sniderman, Raj Bhopal, Dorairaj Prabhakaran, Nizal Sarrafzadegan, André Tchernof - International Journal of Epidemiology 2007 cited by 347